April 6, 2019
  • Erica Benigni
  • Marco Blei

The Court of Milan on the urgent protection of patents infringed by products sold under the framework of a public tender

In an urgent proceeding before the Court of Milan, the claimant, licensee of the European patent 1089726B1 (correspondent to the Italian patent IT 99930567.5) relating to a food supplement essentially composed of HMB, arginine and glutamine, requested the court grant an injunction against the alleged infringer.

More specifically, the claimant challenged the defendant’s sale of a food supplement (which the claimant alleged fell within the scope of its patent) to a public administration as a result of a public tender.

The Court of Milan, prima facie, acknowledged the validity of the patent and its infringement by the defendant’s product, and therefore issued the requested injunction and prohibited the defendant from marketing the challenged product.

It is important to highlight that, throughout the proceeding, the defendant argued that an interim injunction could not be issued since it was bound by a public contract, as awarded by a public tender, to supply the challenged product to a public entity. The defendant claimed that, should the injunction be issued, it would be prevented from supplying the product and it would incur fines and penalties as a result.

In this regard, the court specified that the fact that the defendant would be fined by the public administration for not supplying the challenged product could not be regarded as a justification for the infringement and could not exempt the defendant from the injunction. In fact, without the injunction the defendant would be able to continue supplying the challenged product, causing irreparable damage to the claimant.

In striking a balance between the interests involved, that is between the interests of the claimant to protect and enforce its exclusive patent rights, the interests of the defendant to continue supplying the challenged product and to not incur fines and penalties, and the interests of the public administration to receive the supply of the challenged product, the court gave priority to the claimant’s right to enforce its patent and therefore to the protection of the industrial property right.

< Back to blog
Welcome to the Portolano Cavallo Life Sciences blog focusing on legal development and key legal issues affecting the life sciences and healthcare industry.
Read more
Our highly-ranked team of professionals will provide news, insights and multidisciplinary commentary on the hottest and most recent regulatory, transactional and contentious aspects of the pharmaceutical, bio-tech, med-tech, food supplement and healthcare world with an eye on its digital transformation and technological developments.

This blog will be a place for focusing on digital health, telemedicine and artificial intelligence, as well as more traditional topics: from the protection of intellectual properties to performance of clinical trials, from the market access to advertising and competition issues, from internal and criminal investigations to M&A and venture capital transactions.

October 6, 2023
CBD products: the Administrative Court suspended until October 24 the recent Decree of the Italian Ministry of Health listing cannabidiol for oral use among narcotic drugs, due to the lack o...
October 4, 2023
The Guidelines for regulating contractual relations between universities and research institutes and private sponsors were adopted by the relevant Italian Ministries following the amendment ...
September 21, 2023
CBS products: from September 20th, compositions for oral administration of cannabidiol obtained from Cannabis sativa extracts shall be considered as narcotic drugs in Italy, as they have bee...
July 27, 2023
Payback on medical devices: Italian government announces extension of payment deadline to October 30, 2023
July 21, 2023
On July 21, 2023, the Italian Ministry of Health published new guidelines on health advertising of self-medication drugs (OTC) and non-prescription drugs (SOP), including advertising on new ...
Search by...
Follow us on
Follow us on